Analysis of chronic mast cell leukemia secondary to hematopoietic stem cell transplantation in myelodysplastic syndrome

doi:10.3969/j.issn.1673-8640.2023.10.012

Abstract

Abstract:

Objective To analyze the morphology and prognosis correlation of chronic mast cell leukemia after allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Methods The clinical manifestations and treatment process of this case were analyzed retrospectively，and the laboratory determination results were analyzed. Results The patient had no mast cells before transplantation，and all the laboratory determination results after fully compatible transplantation met the diagnostic criteria for mast cell leukemia. The determination results of chimerism rate indicated that the patient was in a complete chimerism state at the early stage of transplantation. With the increase of the proportion of mast cells in the bone marrow，the chimerism rate was decreased，and the patient was in a mixed chimerism state. Conclusions Relatively mature mast cells may suggest a better prognosis. Systemic mast cell hyperplasia occurs on the basis of clonal hematopoietic tissue diseases，which can easily be ignored and lead to disease progression. Therefore，mast cell proliferation should be vigilant when patients with hematological tumors repeatedly develop allergic symptoms such as cough.

Key words: Myelodysplastic syndrome, Hematopoietic stem cell transplantation, Mast cell leukemia, Morphology, C-KIT

CLC Number:

R446.1

DING Jing, LIU Weiling, XIA Xinxin, LIN Lihui. Analysis of chronic mast cell leukemia secondary to hematopoietic stem cell transplantation in myelodysplastic syndrome[J]. Laboratory Medicine, 2023, 38(10): 971-976.

Figures/Tables 4

References 18

[1]	CAZZOLA M. Myelodysplastic syndromes[J]. N Engl J Med, 2020, 383(14):1358-1374. DOI URL
[2]	LIM K H, TEFFERI A, LASHO T L, et al. Systemic mastocytosis in 342 consecutive adults:survival studies and prognostic factors[J]. Blood, 2009, 113(23):5727-5736. DOI URL
[3]	邵宇, 王健民, 龚胜兰, 等. 一种基于单核苷酸多态性位点的定量检测异基因造血干细胞移植后嵌合率的新方法[J]. 中华血液学杂志, 2010, 31(2):92-96.
[4]	ARBER D A, ORAZI A, HASSERJISAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20) :2391-2405. DOI PMID
[5]	SWERDLOWS H, CAMPO E, HARRIS N L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008.
[6]	VALENT P, SOTLAR K, DPERR W R,et al. Refined diagnostic criteria and classification of mast cell leukemia(MCL) and myelomastocytic leukemia(MML):a consensus proposal[J]. Ann Oncol, 2014, 25(9):1691-1700. DOI URL
[7]	SPERR W R, ESCRIBANO L, JORDAN J H, et al. Morphologic properties of neoplastic mast cells:delineation of stages of maturation and implication for cytological grading of mastocytosis[J]. Leuk Res, 2001, 25(7):529-536. DOI URL
[8]	HÄGGLUND H, YAVUZ A S, DREIMANE A, et al. Graft-versus-mastocytosis effect after donor lymphocyte infusion:proof of principle[J]. Eur J Haematol, 2021, 106(2):290-293. DOI URL
[9]	BAE M H, KIM H K, PARK C J, et al. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation[J]. Ann Lab Med, 2013, 33(2):125-129. DOI PMID
[10]	STOECKER M M, WANG E. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease:a clinicopathologic review[J]. Arch Pathol Lab Med, 2012, 136(7):832-838. DOI URL
[11]	KIM M J, KIM M K, KIM Y K, et al. Systemic mastocytosis associated with acute myeloid leukaemia[J]. Pathology, 2017, 49(6):652-654. DOI URL
[12]	CRAIG J W, HASSERJIAN R P, KIM A S, et al. Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis[J]. Mod Pathol, 2020, 33(6):1135-1145. DOI URL
[13]	FRITSCHE-POLANZ R, FRITZ M, HUBER A, et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V[J]. Mol Oncol, 2010, 4(4):335-346. DOI URL
[14]	JAWHAR M, DÖHNER K, KREIL S, et al. KIT D816 mutated/CBF-negative acute myeloid leukemia:a poor-risk subtype associated with systemic mastocytosis[J]. Leukemia, 2019, 33(5):1124-1134. DOI
[15]	NAGAI S, ICHIKAWAM, TAKAHASHI T, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia[J]. Exp Hematol, 2007, 35(11):1747-1752. PMID
[16]	PULLARKAT V, BEDELL V, KIM Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone[J]. Leuk Res, 2007, 31(2):261-265. DOI URL
[17]	SPERR W R, DRACH J, HAUSWIRTH A W, et al. Myelomastocytic leukemia:evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation[J]. Clin Cancer Res, 2005, 11(19 Pt 1):6787-6792. DOI URL
[18]	CHEN T, CHEN J, HUANG W, et al. Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2003, 32(1):111-114. DOI

项目	初诊	移植前	供者	移植后	形态	处理	预后
本病例	MDS-EB-1	MDS-EB-1	全相合同胞供者	+1.5年诊断为肥大细胞白血病	肥大细胞约占96.5%。细胞中等偏大，多数规则，8%为梭形；核中等，圆形，居中或稍偏位，染色质偏成熟；胞质偏多，布满紫黑色粗大颗粒。21%胞体偏大，核畸形呈哑铃样或双核，染色质偏细，可有少数细胞颗粒缺乏	甲磺酸伊马替尼联合小剂量醋酸泼尼松片	移植后7年内早期完全嵌合状态，后期处于混合嵌合状态，存在肥大细胞、不存在髓系原始细胞
病例1^[8]	真性红细胞增多症进展为急性髓细胞白血病	真性红细胞增多症存在，急性髓细胞白血病缓解	全相合无关供者	+6年嵌合率降低、JAK2V617F变异等位基因频率上升，诊断为肥大细胞白血病伴骨髓增殖性肿瘤	肥大细胞占有核细胞的36%。细胞稍大，具有单个圆形或椭圆形细胞核。颗粒良好，核/质比低。形态介于非典型Ⅰ型、未成熟和成熟肥大细胞之间。纺锤形的肥大细胞<5%。异染原始细胞占有核细胞的1%	供体淋巴细胞输注	移植后6年内持续缓解，无肥大细胞、JAK2V617F阴性、嵌合率100%；移植后4个月因新发颅内出血死亡
病例2^[9]	急性髓细胞白血病伴t（8；21）（q22；q22）	系统性肥大细胞增多症-急性髓细胞白血病	半相合无关供者	+29 d骨髓涂片中肥大细胞占有核细胞的 62.4%；+49 d肥大细胞69.2%。诊断为肥大细胞白血病	+29 d骨髓中异染性母细胞约62.4%，高核/质比、染色质细、核仁不明显、胞浆颗粒减少。+49 d非典型肥大细胞（Ⅱ型）占骨髓有核细胞的69.2%，核双叶或多叶，染色质较致密，无核仁，胞质中有丰富的异染颗粒

项目	初诊	移植前	供者	移植后	形态	处理	预后
本病例	MDS-EB-1	MDS-EB-1	全相合同胞供者	+1.5年诊断为肥大细胞白血病	肥大细胞约占96.5%。细胞中等偏大，多数规则，8%为梭形；核中等，圆形，居中或稍偏位，染色质偏成熟；胞质偏多，布满紫黑色粗大颗粒。21%胞体偏大，核畸形呈哑铃样或双核，染色质偏细，可有少数细胞颗粒缺乏	甲磺酸伊马替尼联合小剂量醋酸泼尼松片	移植后7年内早期完全嵌合状态，后期处于混合嵌合状态，存在肥大细胞、不存在髓系原始细胞
病例1^[8]	真性红细胞增多症进展为急性髓细胞白血病	真性红细胞增多症存在，急性髓细胞白血病缓解	全相合无关供者	+6年嵌合率降低、JAK2V617F变异等位基因频率上升，诊断为肥大细胞白血病伴骨髓增殖性肿瘤	肥大细胞占有核细胞的36%。细胞稍大，具有单个圆形或椭圆形细胞核。颗粒良好，核/质比低。形态介于非典型Ⅰ型、未成熟和成熟肥大细胞之间。纺锤形的肥大细胞<5%。异染原始细胞占有核细胞的1%	供体淋巴细胞输注	移植后6年内持续缓解，无肥大细胞、JAK2V617F阴性、嵌合率100%；移植后4个月因新发颅内出血死亡
病例2^[9]	急性髓细胞白血病伴t（8；21）（q22；q22）	系统性肥大细胞增多症-急性髓细胞白血病	半相合无关供者	+29 d骨髓涂片中肥大细胞占有核细胞的 62.4%；+49 d肥大细胞69.2%。诊断为肥大细胞白血病	+29 d骨髓中异染性母细胞约62.4%，高核/质比、染色质细、核仁不明显、胞浆颗粒减少。+49 d非典型肥大细胞（Ⅱ型）占骨髓有核细胞的69.2%，核双叶或多叶，染色质较致密，无核仁，胞质中有丰富的异染颗粒